Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
Sijongesonke Peter1, Sibusiso Alven1, Rejoice Bethusile Maseko2
1Department of Chemistry, University of Fort Hare, Alice 5700, South Africa.
Abstract:
The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca2+, and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects.
Insights
Developing novel hybrid anticancer agents is crucial due to rising cancer rates. Hybridizing doxorubicin with other drugs shows promise for more effective cancer therapies with fewer side effects.
Area of Science:
- Oncology
- Medicinal Chemistry
Background:
- Cancer remains a leading cause of death globally, necessitating novel therapeutic strategies.
- Doxorubicin is a widely used chemotherapy drug, but faces challenges like drug resistance and toxicity.
- Current treatment limitations highlight the need for innovative approaches to cancer therapy.
Purpose of the Study:
- To review advancements in hybrid compounds combining doxorubicin scaffolds with other chemotherapeutic agents.
- To explore the potential of these hybrid molecules as effective anticancer drugs.
- To provide an update on the development of novel doxorubicin-based hybrid therapeutics.
Main Methods:
- Literature review of scientific publications on doxorubicin hybrid compounds.
- Analysis of studies reporting on the synthesis and efficacy of these hybrid molecules.
- Evaluation of data on chemotherapeutic effects and potential side effects.
Main Results:
- Hybrid compounds integrating doxorubicin scaffolds demonstrate potent chemotherapeutic effects.
- Combination strategies can potentially mitigate resistance and reduce toxicity associated with doxorubicin monotherapy.
- Emerging hybrid molecules show promise for enhanced anticancer activity.
Conclusions:
- Hybridization of doxorubicin with other chemotherapeutic agents is a promising strategy for developing next-generation cancer treatments.
- Further research into doxorubicin-based hybrids could lead to more effective and safer cancer therapies.
- These novel compounds represent a significant advancement in the fight against cancer.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...